Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 2/20 | 0.41 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | CPA1 | P15085 | 1/20 | 0.39 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21930777 | 1.00 | GRIK1 (0.41) | GRIK1GRIK2CYP2C19CPA1ABCC4 | |
| SCHEMBL22367642 | 0.86 | GRIK1 (0.38) | GRIK1GRIK2CYP2C19CPA1ABCC4 | |
| SCHEMBL6810881 | 0.80 | GRIK1 (0.34) | GRIK1GRIK2CYP2C19CPA1TP53 | |
| SCHEMBL7136588 | 0.80 | GRIK1 (0.34) | GRIK1GRIK2CYP2C19CPA1TP53 | |
| SCHEMBL7136593 | 0.80 | GRIK1 (0.34) | GRIK1GRIK2CYP2C19CPA1TP53 | |
| SCHEMBL976765 | 0.79 | GRIK1 (0.39) | GRIK1GRIK2CYP2C19CPA1ABCC4 | |
| SCHEMBL11199369 | 0.79 | GRIK1 (0.39) | GRIK1GRIK2CYP2C19CPA1ABCC4 | |
| SCHEMBL28068346 | 0.79 | GRIK1 (0.39) | GRIK1GRIK2CYP2C19CPA1ABCC4 | |
| SCHEMBL16429595 | 0.79 | GRIK1 (0.39) | GRIK1GRIK2CYP2C19CPA1ABCC4 | |
| SCHEMBL10570752 | 0.78 | TP53 (0.35) | GRIK1TP53RNPEPCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3702381-B1 | COPOLYMER OF OLEFIN AND UNSATURATED CARBOXYLIC ACID OR UNSATURATED CARBOXYLIC ACID DERIVATIVE | CHINA PETROLEUM & CHEM CORP (CN) | 2025-12-03 | — | — | EP | disclosed |
| US-12473387-B2 | Copolymer of olefin and unsaturated carboxylic acid or unsaturated carboxylic acid derivative | CHINA PETROLEUM & CHEMICAL CORPORATION (CN) | 2025-11-18 | — | — | US | disclosed |
| US-12428505-B2 | Method for preparing olefin-polar monomer copolymer | CHINA PETROLEUM & CHEMICAL CORPORATION (CN) | 2025-09-30 | — | — | US | disclosed |
| CN-116199806-B | Coordination precipitation polymerization method for olefin polymerization and obtained polyolefin | 中国石油化工股份有限公司 | 2025-05-06 | — | — | CN | disclosed |
| CN-119798491-A | Coordination precipitation polymerization process for olefin polymerization and polyolefin | 中国石油化工股份有限公司 | 2025-04-11 | — | — | CN | disclosed |
| CN-119798492-A | Coordination precipitation polymerization process for olefin polymerization and polyolefin | 中国石油化工股份有限公司 | 2025-04-11 | — | — | CN | disclosed |
| CN-119798493-A | Coordination precipitation polymerization process for olefin polymerization and polyolefin | 中国石油化工股份有限公司 | 2025-04-11 | — | — | CN | disclosed |
| CN-119661751-A | Coordination precipitation polymerization process for olefin polymerization and polyolefin | 中国石油化工股份有限公司 | 2025-03-21 | — | — | CN | disclosed |
| CN-119661749-A | Coordination precipitation polymerization process for olefin polymerization and polyolefin | 中国石油化工股份有限公司 | 2025-03-21 | — | — | CN | disclosed |
| CN-119661750-A | Coordination precipitation polymerization process for olefin polymerization and polyolefin | 中国石油化工股份有限公司 | 2025-03-21 | — | — | CN | disclosed |
| US-20200148705-A1 | Spiro-Sulfonamide Derivatives As Inhibitors Of Myeloid Cell Leukemia-1 (MCL-1) Protein | PRELUDE THERAPEUTICS, INCORPORATED | 2020-05-14 | — | — | US | disclosed |
| US-20200148705-A1 | Spiro-Sulfonamide Derivatives As Inhibitors Of Myeloid Cell Leukemia-1 (MCL-1) Protein | PRELUDE THERAPEUTICS, INCORPORATED | 2020-05-14 | — | — | US | disclosed |
| CN-111116801-A | Preparation method of olefin-unsaturated carboxylic acid copolymer | 中国石油化工股份有限公司 | 2020-05-08 | — | — | CN | disclosed |
| CN-111116802-A | Preparation method of olefin-unsaturated carboxylic acid copolymer | 中国石油化工股份有限公司 | 2020-05-08 | — | — | CN | disclosed |
| CN-111116806-A | Preparation method of olefin-unsaturated carboxylic acid copolymer | 中国石油化工股份有限公司 | 2020-05-08 | — | — | CN | disclosed |
| CN-111116803-A | Preparation method of olefin-unsaturated carboxylic acid copolymer | 中国石油化工股份有限公司 | 2020-05-08 | — | — | CN | disclosed |
| US-7038064-B2 | Process for producing hydroxylactones | DIACEL CHEMICAL INDUSTRIES, LTD. (JP) | 2006-05-02 | — | — | US | disclosed |
| EP-1302469-B1 | PROCESS FOR PRODUCING HYDROXYLACTONE | DAICEL CHEM (JP) | 2005-03-30 | — | — | EP | disclosed |
| US-20040024228-A1 | Process for producing hydroxylactones | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2004-02-05 | — | — | US | disclosed |
| EP-1302469-A1 | PROCESS FOR PRODUCING HYDROXYLACTONE | Daicel Chemical Industries, Ltd. (JP) | 2003-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200148705-A1 | Spiro-Sulfonamide Derivatives As Inhibitors Of Myeloid Cell Leukemia-1 (MCL-1) Protein | MCL1, BCL2A1, BCL2L1 | GRIK1 3304/4885GRIK2 4165/4885CYP2C19 4028/4885 |
| US-20040024228-A1 | Process for producing hydroxylactones | HAO2, HAO1, DUOX2 | GRIK1 2257/4885GRIK2 1725/4885CYP2C19 354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.